Company producing a wound care dressing from placentas with an extremely high gross margin.
Investment Insights
AI-generated insights about BioStem Technologies from various financial sources
Wednesday, July 16, 2025
An asymmetric, high-risk/high-reward bet. The stock is extremely cheap (P/S of 0.5) but faces a significant risk of losing Medicare reimbursement. Potential catalysts include a NASDAQ uplisting and a positive CMS decision, which could lead to a 5x to 10x return.
Friday, June 27, 2025
Mentioned as being even cheaper than CoreMedix, but it carries a major 'binary risk' due to the potential loss of Medicare reimbursement in 2026, which could be catastrophic for the company.
Wednesday, July 16, 2025
An asymmetric, high-risk/high-reward bet. The stock is extremely cheap (P/S of 0.5) but faces a significant risk of losing Medicare reimbursement. Potential catalysts include a NASDAQ uplisting and a positive CMS decision, which could lead to a 5x to 10x return.
Friday, June 27, 2025
Mentioned as being even cheaper than CoreMedix, but it carries a major 'binary risk' due to the potential loss of Medicare reimbursement in 2026, which could be catastrophic for the company.